Horizon Kinetics Asset Management LLC Lowers Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Horizon Kinetics Asset Management LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,239 shares of the company’s stock after selling 443 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in CRISPR Therapeutics were worth $481,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of CRISPR Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after buying an additional 46,148 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of CRISPR Therapeutics by 2.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock worth $51,326,000 after acquiring an additional 19,094 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of CRISPR Therapeutics by 0.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 724,241 shares of the company’s stock worth $34,025,000 after buying an additional 6,635 shares during the period. Farallon Capital Management LLC purchased a new position in CRISPR Therapeutics during the 2nd quarter valued at about $28,625,000. Finally, Baillie Gifford & Co. boosted its stake in shares of CRISPR Therapeutics by 2.4% in the second quarter. Baillie Gifford & Co. now owns 405,425 shares of the company’s stock valued at $21,897,000 after purchasing an additional 9,510 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $50.40 on Tuesday. CRISPR Therapeutics AG has a 12 month low of $43.42 and a 12 month high of $91.10. The company has a 50-day moving average of $47.98 and a 200-day moving average of $51.73. The company has a market cap of $4.30 billion, a P/E ratio of -17.81 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the prior year, the firm posted ($1.41) earnings per share. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.2 EPS for the current year.

Analyst Upgrades and Downgrades

CRSP has been the subject of several analyst reports. Barclays lowered their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 target price on the stock. Chardan Capital decreased their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Truist Financial decreased their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $74.94.

Insider Buying and Selling

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 1.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the sale, the chief executive officer now owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. This trade represents a 13.24 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 35,382 shares of company stock valued at $1,917,679. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.